Abstract 418P
Background
There is sparse data available on foot sarcomas treated on contemporary protocols.
Methods
This retrospective analysis involved 27 cases of foot sarcomas managed with multi-modality treatment under Sarcoma Clinic, at tertiary care hospital between January 2014 to May 2019. Baseline demographics, radiographic tumour characteristics, histological diagnosis, type of treatment received and oncological outcomes were noted for all cases. Statistical analysis was done by STATA version 13.0. Survival curves were analyzed by Kaplan Meir test and univariate analysis was done by Log Rank test.
Results
Median age was 26 years (range: 20 – 46 years). Median duration of symptoms were 11 months (Range: 5 – 24 months). Radiologically mean largest diameter of tumour was 6.5 cm (CI: 1.1 – 12 cm). Seven tumours (26%) arose from bone and 20 form soft tissue (74%). In tumours arising from bone, metatarsal was most commonly site of involvement (3 out of 7). Most common histology was synovial sarcoma (44%) f/b Ewing’s sarcoma (26%) f/b others (RMS, DFSP, MPNST, angiosarcoma). Ten patients (37%) had metastatic disease at presentation, lung being most common site (80%). Histological discordance with review diagnosis was seen in 50 % cases. Amputation was needed in 10 cases (37%) (palliative - 5, curative - 5) while limb salvage surgery was done in 10 (all curative). Adjuvant radiation was given in 7 out of 10 cases (70%). At last follow up 16 out of 27 patients (60%) were alive without disease, 4 (11%) with disease while 8 (29%) have died. With median follow-up of 43 months (Range 8 - 63 months) median PFS was 22 months. Median PFS in non-metastatic group was 48 months, while in metastatic group it was 8 months. On univariate analysis, median OS was significantly different between metastatic vs non-metastatic group (HR 10.93, p = 0.03).
Conclusions
Foot sarcomas happen in young adults irrespective of pathology with synovial sarcoma and Ewing’s sarcoma being most common histologies. Amputation rates are quite high even considering small size, owing to anatomy of the region as noted in previous studies. The treatment required for non metastatic disease is multimodality including use of radiation. If treated in multidisciplinary clinic outcomes can certainly be improved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sameer Rastogi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract